Comparative Pharmacology
Head-to-head clinical analysis: ETRAVIRINE versus RESCRIPTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAVIRINE versus RESCRIPTOR.
ETRAVIRINE vs RESCRIPTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing conformational change and inhibiting RNA-dependent DNA polymerase activity.
400 mg orally twice daily after meals.
400 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life approximately 41 hours (range 20-70 hours) following multiple doses; supports once-daily dosing with a pharmacokinetic booster (e.g., ritonavir or cobicistat).
Clinical Note
moderateEtravirine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Cyclosporine
"The serum concentration of Cyclosporine can be increased when it is combined with Etravirine."
Clinical Note
moderateEtravirine + Fluconazole
Terminal elimination half-life is 2.5–4.5 hours in adults. This short half-life necessitates twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Fecal: ~93.7% (unchanged drug and metabolites; bile is the major route); Renal: ~1.2% (urinary, negligible unchanged drug).
Renal: 51% (unchanged drug) and 44% (glucuronide metabolite); biliary/fecal: <5%. Total recovery in urine is approximately 95%.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral
"The serum concentration of Fluconazole can be increased when it is combined with Etravirine."